tumour necrosis factor inhibitors

Serious infections in patients with rheumatoid arthritis and psoriatic arthritis treated with tumour necrosis factor inhibitors: data from register linkage of the NOR-DMARD study
Ingrid Egeland Christensen, Siri Lillegraven, Pawel Mielnik, Gunnstein Bakland, Liz Loli, Joe Sexton, Till Uhlig, Tore K Kvien, Sella A Provan

Annals of the Rheumatic Diseases Mar 2022, 81 (3) 398-401; DOI: 10.1136/annrheumdis-2021-221007
Abatacept is second to rituximab at risk of HBsAg reverse seroconversion in patients with rheumatic disease
Ming-Han Chen, I-Cheng Lee, Ming-Huang Chen, Ming-Chih Hou, Chang-Youh Tsai, Yi-Hsiang Huang

Annals of the Rheumatic Diseases Nov 2021, 80 (11) 1393-1399; DOI: 10.1136/annrheumdis-2021-220774
Impact of disease-modifying antirheumatic drugs on vaccine immunogenicity in patients with inflammatory rheumatic and musculoskeletal diseases
Marcia A Friedman, Jeffrey R Curtis, Kevin L Winthrop

Annals of the Rheumatic Diseases Oct 2021, 80 (10) 1255-1265; DOI: 10.1136/annrheumdis-2021-221244
Efficacy and safety of biological DMARDs: a systematic literature review informing the 2022 update of the ASAS-EULAR recommendations for the management of axial spondyloarthritis
Casper Webers, Augusta Ortolan, Alexandre Sepriano, Louise Falzon, Xenofon Baraliakos, Robert B M Landewé, Sofia Ramiro, Désirée van der Heijde, Elena Nikiphorou

Annals of the Rheumatic Diseases Jan 2023, 82 (1) 130-141; DOI: 10.1136/ard-2022-223298
Response to: ‘Correspondence on ‘Tapering towards DMARD-free remission in rheumatoid arthritis’ by Garcia et al
Elise van Mulligen, Pascal Hendrik Pieter de Jong

Annals of the Rheumatic Diseases Jan 2023, 82 (1) e10; DOI: 10.1136/annrheumdis-2020-219293
Telerheumatology in COVID-19 era: a study from a psoriatic arthritis cohort
Luisa Costa, Marco Tasso, Nadia Scotti, Erika Mostacciuolo, Nicolò Girolimetto, Francesca Foglia, Antonio del Puente, Raffaele Scarpa, Francesco Caso

Annals of the Rheumatic Diseases Apr 2021, 80 (4) e46; DOI: 10.1136/annrheumdis-2020-217806
Modern treatment approach results in low disease activity in 90% of pregnant rheumatoid arthritis patients: the PreCARA study
Hieronymus TW Smeele, Esther Röder, Hetty M Wintjes, Laura JC Kranenburg-van Koppen, Johanna MW Hazes, Radboud JEM Dolhain

Annals of the Rheumatic Diseases Jul 2021, 80 (7) 859-864; DOI: 10.1136/annrheumdis-2020-219547
Early reduction in circulating monocyte count predicts maintenance of remission in patients with rheumatoid arthritis treated with anti-TNF therapy
Muhammad Ruhul Amin Shipa, Raj Amarnani, Su-Ann Yeoh, M D Mainuddin, Michael R Ehrenstein

Annals of the Rheumatic Diseases Dec 2021, 80 (12) 1628-1629; DOI: 10.1136/annrheumdis-2021-220642
Efficacy and safety of guselkumab in patients with active psoriatic arthritis who are inadequate responders to tumour necrosis factor inhibitors: results through one year of a phase IIIb, randomised, controlled study (COSMOS)
Laura C Coates, Laure Gossec, Elke Theander, Paul Bergmans, Marlies Neuhold, Chetan S Karyekar, May Shawi, Wim Noël, Georg Schett, Iain B McInnes

Annals of the Rheumatic Diseases Mar 2022, 81 (3) 359-369; DOI: 10.1136/annrheumdis-2021-220991
What is the optimal target for a T2T approach in axial spondyloarthritis?
Joachim Sieper, Denis Poddubnyy

Annals of the Rheumatic Diseases Nov 2021, 80 (11) 1367-1369; DOI: 10.1136/annrheumdis-2021-220603

Main menu

tumour necrosis factor inhibitors

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

tumour necrosis factor inhibitors

Pages